Using a recently approved tumor mutational burden biomarker to stratify patients for immunotherapy may introduce a sex bias

Neelam Sinha; Sanju Sinha; Kuoyuan Cheng; Sanna Madan; Ayelet Erez; Bríd M. Ryan; Alejandro A. Schäffer; Kenneth Aldape; Eytan Ruppin

doi:10.1200/PO.21.00168

Using a recently approved tumor mutational burden biomarker to stratify patients for immunotherapy may introduce a sex bias

Neelam Sinha, Sanju Sinha, Kuoyuan Cheng, Sanna Madan, Ayelet Erez, Bríd M. Ryan, Alejandro A. Schäffer, Kenneth Aldape, Eytan Ruppin^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	1147-1150
Number of pages	4
Journal	JCO Precision Oncology
Volume	5
DOIs	https://doi.org/10.1200/PO.21.00168
State	Published - 2021
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/PO.21.00168

Cite this

@article{233b718c911b45c981098dba606060cf,

title = "Using a recently approved tumor mutational burden biomarker to stratify patients for immunotherapy may introduce a sex bias",

author = "Neelam Sinha and Sanju Sinha and Kuoyuan Cheng and Sanna Madan and Ayelet Erez and Ryan, {Br{\'i}d M.} and Sch{\"a}ffer, {Alejandro A.} and Kenneth Aldape and Eytan Ruppin",

note = "Funding Information: This research used the computational resources of the NIH HPC Biowulf cluster (http://hpc.nih.gov). This research was supported by the Intramural Research Program of the National Institutes of Health, NCI, Center for Cancer Research. S.S. is supported by the NCI-UMD Partnership for Integrative Cancer Research Program.",

year = "2021",

doi = "10.1200/PO.21.00168",

language = "אנגלית",

volume = "5",

pages = "1147--1150",

journal = "JCO Precision Oncology",

issn = "2473-4284",

publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - Using a recently approved tumor mutational burden biomarker to stratify patients for immunotherapy may introduce a sex bias

AU - Sinha, Neelam

AU - Sinha, Sanju

AU - Cheng, Kuoyuan

AU - Madan, Sanna

AU - Erez, Ayelet

AU - Ryan, Bríd M.

AU - Schäffer, Alejandro A.

AU - Aldape, Kenneth

AU - Ruppin, Eytan

N1 - Funding Information: This research used the computational resources of the NIH HPC Biowulf cluster (http://hpc.nih.gov). This research was supported by the Intramural Research Program of the National Institutes of Health, NCI, Center for Cancer Research. S.S. is supported by the NCI-UMD Partnership for Integrative Cancer Research Program.

PY - 2021

Y1 - 2021

UR - http://www.scopus.com/inward/record.url?scp=85112416612&partnerID=8YFLogxK

U2 - 10.1200/PO.21.00168

DO - 10.1200/PO.21.00168

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 34994632

AN - SCOPUS:85112416612

SN - 2473-4284

VL - 5

SP - 1147

EP - 1150

JO - JCO Precision Oncology

JF - JCO Precision Oncology

ER -

Using a recently approved tumor mutational burden biomarker to stratify patients for immunotherapy may introduce a sex bias

UN SDGs

Access to Document

Other files and links

Cite this